Mannatech cuts costs with layoffs
This article was originally published in The Tan Sheet
Executive Summary
The Coppell, Texas-based multi-level marketer will immediately eliminate roughly 15 percent of its U.S. workforce, or approximately 60 positions, as part of an effort to reduce expenses and "reposition the company for improved profitability," the supplement and skin care firm says July 10. The firm's cost-cutting measures also follow recent legal troubles. Mannatech agreed to pay $11.25 million in March to settle class action allegations that it caused its stock to trade at inflated levels between Aug. 10, 2004 and July 30, 2007 by failing to adequately monitor how its associates advertised its products (1"The Tan Sheet" March 24, 2008, In Brief)...
You may also be interested in...
SEC clears Mannatech
The Securities and Exchange Commission will not recommend enforcement action against Mannatech executives following an investigation into the "timing and completeness" of the multi-level marketer's disclosure of its dismissal of its public accountants in October 2007, the firm says Nov. 4. The Coppell, Texas-based company announced in July a 15 percent cut in its U.S. workforce and in March settled class action allegations of stock price inflation (1"The Tan Sheet" July 14, 2008, In Brief)
Mannatech settles class action
Dietary supplement marketer Mannatech will pay $11.25 million to settle class action allegations that it caused its stock to trade at inflated levels between Aug. 10, 2004 and July 30, 2007 by failing to adequately monitor how its associates advertised its products. Approval by the U.S. District Court for the Northern District of Texas is required for the settlement to be finalized, but the Coppell, Texas-based firm says March 21 it expects approval without material changes within four to six months...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.